Chandarlapaty, S. and Errede, B.J.  ASH1, a Daughter Cell-Specific Protein, Is Required for Pseudohyphal Growth of Saccharomyces cerevisiae.  Mol. Cell.Biology1998 May;18(5):2884-91.

Sawai, A., Chandarlapaty, S., Greulich, H., Gonen, M., Ye, Q., Arteaga, C, Sellers, W., Rosen, N., Solit, D. (2008)  Inhibition of Hsp90 downregulates mutant EGFR expression and sensitizes EGFR-mutant tumors to paclitaxel. Cancer Res 2008 Jan 15;68(2):589-96.

Chandarlapaty, S., Sawai, A., Ye, Q., Scott, A., Silinski, M. Hwang, K., Fadden, P., Norton, L., Rosen, N., Solit, D. (2008) SNX2112, a synthetic Hsp90 inhibitor, has potent anti-tumor activity against HER kinase dependent cancers.  Clin Can Res 2008 Jan 1;14(1):240-8.

She, QB., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, KM., Leander, KR., DeFeo- Jones, D., Huber, HE., Rosen, N.  (2008) Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling.  PLoS ONE 2008 Aug 26;3(8):e3065.

Chandarlapaty, S., Scaltriti, M., Angelini, P., Ye, Q., Guzman, M., Hudis, C., Norton, L., Solit, D., Arribas, J., Baselga, J., Rosen, N.  (2010) Inhibitors of HSP90 block p95- HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2010 Jan 21 29(3):325-34.

Sakr, R.A., Barbashina, V., Morrogh, M., Chandarlapaty, S., Andrade, V.P., Arroyo, C.D., Olvera, N., King, T.A.  (2010) Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma. Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):371-4.

Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P.D., Sánchez, G., Guzman, M., Parra, J.L., Ellis, C., Gagnon, R., Koehler, M., Gomez, H., Geyer, C., Cameron, D., Arribas, J., Rosen, N., Baselga, J. (2010) Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2- positive breast tumors coexpressing the truncated p95HER2 receptor.  Clin Can Res 16:2688-2695.

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., Rosen, N. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.  Cancer Cell, Jan 18;19(1):58-71.

Serra V, Scaltriti M, Prudkin L, Eichorn P, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.

Scaltriti M, Eichorn P, Cortes, J, Prudkin L, Aura C, Jimenez J, Chandarlapaty S, Serra V, Prat A, Ibrahim Y, Guzman M, Guili ML, Rodriguez O, , Rodriguez S, Perez J, Green S, Mai S, Rosen N, Hudis C, Baselga J. (2011) Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 positive breast cancer patients. PNAS, Mar 1; 108(9): 3761-6.

Gajria D, Chandarlapaty S. (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.  Exp Rev Anticancer Ther, Feb;11(2): 263-75. (n.b. peer-reviewed review article)

Modi S, Stopeck AT, Linden HM, Solit DB, Chandarlapaty S, Rosen N, D'Andrea G, Dickler MN, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. (2011) HSP90 Inhibition is Effective in Breast Cancer: A Phase 2 Trial of Tanespimycin (17AAG) plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab.  Clin Cancer Res. 2011 Aug 1;17(15):5132-9. Epub 2011 May 10.

Carver B, Chapinski C, Wongvipat J, Hieronymous H, Chen Y, Chandarlapaty S, Arora V, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.  Cancer Cell, May 17;19(5): 575-586.

Rodrik-Outmezguine R, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N. (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011 Jun 17;1(3):248-259.